TY - JOUR
T1 - A pet/ct volumetric parameter predicts prognosis of non-small cell lung cancer treated using preoperative chemoradiotherapy and surgery
T2 - A retrospective case series study
AU - Katsui, Kuniaki
AU - Ogata, Takeshi
AU - Tada, Akihiro
AU - Watanabe, Kenta
AU - Yoshio, Kotaro
AU - Kuroda, Masahiro
AU - Kiura, Katsuyuki
AU - Hiraki, Takao
AU - Toyooka, Shinichi
AU - Kanazawa, Susumu
N1 - Funding Information:
The present study was supported by a donation from Tsuyama Chuo Hospital. The study sponsor was not involved in any procedure in the present study.
Publisher Copyright:
© 2021, Spandidos Publications. All rights reserved.
PY - 2021
Y1 - 2021
N2 - The purpose of the present study was to clarify whether positron emission tomography/computed tomog-raphy (PET/CT) volumetric parameters were prognostic predictors of non-small cell lung cancer (NSCLC) treatment in patients who had undergone preoperative concurrent chemoradiotherapy (CCRT) and surgery. In the present study, retrospectively surveyed the data of patients with NSCLC who underwent preoperative CCRT and surgery at Okayama University Hospital (Okayama, Japan) between April 2006 and March 2018. The maximum standardized uptake value (SUVmax) and volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were calculated using PET/CT and the percentage decrease (Δ) in each parameter value post-CCRT. The SUVmax threshold for defining MTV was set at 2.5. Furthermore, the association between survival and PET parameter values was analyzed. A total of 52 patients were included in the present study. The median follow-up period was 50.65 months. In univariate analysis, ΔTLG was identified to be a significant predictor of progression-free survival (PFS; P=0.03). The 5-year PFS rates were 48.6 and 76.6% for patients with low ΔTLG and high ΔTLG, respectively. High ΔTLG was indicative of a higher overall survival rate (P=0.08). The present results suggest that ΔTLG calculated using PET/CT is a prognostic predictor of NSCLC treated using preoperative CCRT and surgery, and may help physicians determine treatment strategies.
AB - The purpose of the present study was to clarify whether positron emission tomography/computed tomog-raphy (PET/CT) volumetric parameters were prognostic predictors of non-small cell lung cancer (NSCLC) treatment in patients who had undergone preoperative concurrent chemoradiotherapy (CCRT) and surgery. In the present study, retrospectively surveyed the data of patients with NSCLC who underwent preoperative CCRT and surgery at Okayama University Hospital (Okayama, Japan) between April 2006 and March 2018. The maximum standardized uptake value (SUVmax) and volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were calculated using PET/CT and the percentage decrease (Δ) in each parameter value post-CCRT. The SUVmax threshold for defining MTV was set at 2.5. Furthermore, the association between survival and PET parameter values was analyzed. A total of 52 patients were included in the present study. The median follow-up period was 50.65 months. In univariate analysis, ΔTLG was identified to be a significant predictor of progression-free survival (PFS; P=0.03). The 5-year PFS rates were 48.6 and 76.6% for patients with low ΔTLG and high ΔTLG, respectively. High ΔTLG was indicative of a higher overall survival rate (P=0.08). The present results suggest that ΔTLG calculated using PET/CT is a prognostic predictor of NSCLC treated using preoperative CCRT and surgery, and may help physicians determine treatment strategies.
KW - Non-small cell lung cancer
KW - Positron emission tomography
KW - Preoperative concurrent chemoradiotherapy
KW - Δtotal lesion glycolysis
UR - http://www.scopus.com/inward/record.url?scp=85102433983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102433983&partnerID=8YFLogxK
U2 - 10.3892/mco.2021.2235
DO - 10.3892/mco.2021.2235
M3 - Article
AN - SCOPUS:85102433983
SN - 2049-9450
VL - 14
SP - 1
EP - 8
JO - Molecular and Clinical Oncology
JF - Molecular and Clinical Oncology
IS - 4
M1 - 73
ER -
